William Blair just gave Vertex Pharmaceuticals a shiny bump in its 2025 earnings forecast, increasing EPS to $16.20 from ...

Vertex, Inc. (NASDAQ: VERX), a leading provider of indirect tax solutions, announced robust financial results for the first ...

A decade has passed since a short-lived railcar manufacturer opened its doors in Wilmington. At an invitation-only event in November 2014, many promises were made on behalf of Vertex Rail Technologies ...

Vertex, Inc. (VERX) kicks off 2025 strong with 12.9% revenue growth, strategic AI investments, and e-invoicing innovations.

Barclays has nudged Vertex Pharmaceuticals’ price target to $499, despite a mixed bag in its Q1 performance. Vertex saw a 3% ...

The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 13 cents per share. The company posted revenue of $177.1 ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...